Surrogate Efficacy Endpoints in Oncology Trials

Author： Markman Maurie  

Publisher： Adis International

ISSN： 1178-2595

Source： Pharmaceutical Medicine, Vol.23, Iss.5-6, 2009-10, pp. : 283-287

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel Procedures for Validating Surrogate Endpoints in Clinical Trials

By  

Current Clinical Pharmacology, Vol. 2, Iss. 2, 2007-05 ,pp. : 123-128

Bentham Science Publishers

Access to resources Recommend Favorite

Evaluation of Early Efficacy Endpoints for Proof-of-Concept Trials

By Chen Cong  

Journal of Biopharmaceutical Statistics, Vol. 23, Iss. 2, 2013-03 ,pp. : 413-424

Taylor & Francis Ltd

Access to resources Recommend Favorite

Tissue-Based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials

By  

Current Drug Targets, Vol. 13, Iss. 12, 2012-11 ,pp. : 1525-1534

Bentham Science Publishers

Access to resources Recommend Favorite

Composite Endpoints for Clinical Trials: Current Perspectives

By Kleist Peter  

International Journal of Pharmaceutical Medicine, Vol. 21, Iss. 3, 2007-01 ,pp. : 187-198

Adis International

Access to resources Recommend Favorite

A Review of: “ The Evaluation of Surrogate Endpoints , by T. Burzykowski, G. Molenberghs, and M. Buyse”

By Klar Neil  

Journal of Biopharmaceutical Statistics, Vol. 16, Iss. 2, 2006-03 ,pp. : 269-271

Taylor & Francis Ltd

Access to resources Recommend Favorite